Literature DB >> 20564163

Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma.

Heather Magnan1, Alexander J Chou, Joanne F Chou, Henry W D Yeung, John H Healey, Paul A Meyers.   

Abstract

BACKGROUND: Histologic response to preoperative chemotherapy is a strong prognostic factor for osteosarcoma (OS). Thallium-201 (Tl-201) scintigraphic response to initial chemotherapy has previously been described as a predictor of histologic response. In the current study, the authors re-examined a series of patients studied using Tl-201 scintigraphy to determine the correlation between changes observed on Tl-201 scintigraphy and event-free survival (EFS).
METHODS: A total of 22 patients with biopsy-proven OS of the extremity underwent Tl-201 imaging before and immediately after preoperative chemotherapy. The maximum pixel counts taken over the tumor divided by those taken of a background region yielded a tumor-to-background ratio (TBR). The percentage of change in the TBR before and after adjuvant chemotherapy, defined as the alteration ratio (AR), was correlated with EFS.
RESULTS: The median AR was 85% (range, 28-100%). The 3-year EFS was 0.72 (95% confidence interval [95% CI], 0.48-0.86) and the 5-year EFS was 0.67 (95% CI, 0.43-0.86). There was no association between AR and EFS detected in this cohort (hazard ratio, 0.99; 95% CI, 0.95-1.02 [Somers rank correlation coefficient, 0.15]).
CONCLUSIONS: Although Tl-201 scintigraphy was used as a tool for the assessment of response to chemotherapy in patients with OS, the AR did not appear to be predictive of EFS in this small group of patients. It is necessary to use the outcome variables of ultimate interest-EFS and overall survival- and not rely on surrogates for outcome to evaluate potential prognostic factors. Cancer, 2010. (c) 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20564163     DOI: 10.1002/cncr.25375

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  XB130 expression in human osteosarcoma: a clinical and experimental study.

Authors:  Xiaohui Wang; Ruiguo Wang; Zhaolong Liu; Fengyun Hao; Hai Huang; Wenchen Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis.

Authors:  H Zhu; H Cai; M Tang; J Tang
Journal:  Clin Transl Oncol       Date:  2013-12-12       Impact factor: 3.405

3.  Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.

Authors:  Junyu Guo; Wilburn E Reddick; John O Glass; Qing Ji; Catherine A Billups; Jianrong Wu; Fredric A Hoffer; Sue C Kaste; Jesse J Jenkins; Ximena C Ortega Flores; Juan Quintana; Milena Villarroel; Najat C Daw
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

4.  Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma.

Authors:  J Tang; H Cai; L Lin; P Xie; W Zhong; M Tang
Journal:  Clin Transl Oncol       Date:  2012-11-10       Impact factor: 3.405

5.  Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with (99m)Tc-MIBI scintigraphy.

Authors:  Hiroshi Wakabayashi; Junko Saito; Junichi Taki; Nanako Hashimoto; Hiroyuki Tsuchiya; Toshifumi Gabata; Seigo Kinuya
Journal:  Skeletal Radiol       Date:  2015-09-18       Impact factor: 2.199

6.  Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.

Authors:  Inki Lee; Byung Hyun Byun; Ilhan Lim; Byung Il Kim; Chang-Bae Kong; Won Seok Song; Wan Hyeong Cho; Jae-Soo Koh; Sang Moo Lim
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

7.  Prognostic value of radiological response to chemotherapy in patients with osteosarcoma.

Authors:  Shinji Miwa; Akihiko Takeuchi; Toshiharu Shirai; Junichi Taki; Norio Yamamoto; Hideji Nishida; Katsuhiro Hayashi; Yoshikazu Tanzawa; Hiroaki Kimura; Kentaro Igarashi; Akishi Ooi; Hiroyuki Tsuchiya
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

8.  Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients' prognosis.

Authors:  Haibo Zhu; Jie Tang; Mingjie Tang; Haikang Cai
Journal:  Diagn Pathol       Date:  2013-11-04       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.